14 February 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the "Company")
CBR Intranasal
Delivery
Chimeric Bait Receptors for
Combatting Airborne Viral Infections Can Be Delivered
Intranasally
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the clinical stage biopharmaceutical
group, announces that it has demonstrated
in vivo that its
proprietary Chimeric Bait Receptor ("CBR") can be delivered
intranasally in the form of messenger RNA ("mRNA") for the
potential treatment of airborne viral infections.
CBR-based countermeasures against
viral infections that are include a novel method of their
delivery. To satisfy real-world requirements for the deployment of
such countermeasures, they must be both easy to administer and have
a long shelf life at ambient temperatures. CBR is a platform
technology under development that aims to program the immune cells
that are responsible for innate immunity (e.g., macrophages) to
eliminate viruses and certain malignant cells.
Our team of scientists has
demonstrated in vivo that
mRNA encoding a CBR-based therapeutic can be mixed with a polymer
and a solvent at room temperature to form polymer nanoparticles
encapsulating mRNA. Such nanoparticles can be used to deliver
CBR-coding mRNA into the upper respiratory tract ("URT") and lungs
of small animals. Once administered, nanoparticles were shown to
successfully deliver mRNA into the immune cells of the URT and
lungs. The immune cells in turn begin making CBR molecules within
hours post-application, potentially becoming active "defenders"
against airborne infections.
As previously reported, the Company
has been able to dramatically accelerate its research and
development efforts by using Artificial
Intelligence ("AI") and in-house synthesis of mRNA. AI tools allow
the Company's scientists to triage variants of CBR constructs
efficiently to select those with the greatest likelihood of
success, while in-house mRNA synthesis facilitates the rapid
building of CBR constructs.
Dr
Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented: "This major breakthrough in the method of delivery of our CBR
demonstrates that it could potentially be used as an off-the-shelf
prevention and/or treatment for viral infections. Intranasal
delivery of CBR would be both cost-efficient and easy to
administer, making it ideal for the protection of both the civilian
population and in biodefense."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in
this announcement would have been inside information for the
purposes of Article 7 of Regulation No 596/2014 (as it forms part
of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical-stage
biopharmaceutical group developing new medicines and treatments for
life-threatening diseases. Hemogenyx Pharmaceuticals is developing
several distinct and complementary product candidates, as well as a
platform technology that it uses as an engine for novel product
development.